首页 Intellia Therapeutics(usNTLA)-基本信息

Intellia Therapeutics(usNTLA)-基本信息

日报更新时间:04-20 10:53

周报更新时间:04-18 04:06

行情信息

今开价:66.38

最高价:73.13

成交量:714651.0

昨收价:67.41

最低价:64.87

最新价:69.16

行情图标
概要信息

英文名称:Intellia Therapeutics


简介:Intellia Therapeutics, Inc.于2014年5月在特拉华州注册成立


电话:1-857-2856200


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Intellia Therapeutics是一家基因编辑公司,专注于利用CRISPR / Cas9系统的生物学工具开发治疗药物。公司认为CRISPR/ Cas9技术具有通过单一疗程药物转换来永久编辑患病基因的潜力,公司打算利用其领先的科学专业知识,临床开发经验和知识产权来打开CRISPR/ Cas9基因组编译技术在广泛的、有潜力的新药开发方面的应用和发展。CRISPR/ Cas9技术过去两年一直是科学研究领域一个前所未有的课题,目前有超过1500种出版物和40种概念刊物提到它,相关的研究产品也超过了20种。CRISPR/ Cas9可以在体内或体外以前所未有的精度移除、更换或修理异常的DNA,可用于治疗数以百计的严重和威胁生命的遗传疾病。Intellia Therapeutics公司开发了针对肝脏疾病的体内计划,包括转甲状腺素蛋白淀粉样变性,α-1抗胰蛋白酶缺乏症,乙型肝炎病毒和先天性代谢异常程序。Intellia Therapeutics离体管道包括专有程序,专注于开发工程细胞疗法,以治疗各种肿瘤和自身免疫疾病; 和合作计划的重点是嵌合抗原受体T细胞和造血干细胞。Intellia Therapeutics, Inc.合作协方包括:Novartis Institutes for BioMedical Research, Inc.;Regeneron Pharmaceuticals, Inc.;Caribou Biosciences, Inc.。

交易日期 交易人 职位 类型 交易份额 价格
2017-07-10 Formela (Jean-Francois) Director Sell 80000 16.07
2017-07-10 Atlas Venture Fund IX, L.P. Beneficial Owner of More than 10% Class Sell 80000 16.07
2017-07-09 Formela (Jean-Francois) Director Sell 40000 16.17
2017-07-09 Atlas Venture Fund IX, L.P. Beneficial Owner of More than 10% Class Sell 40000 16.17
2017-07-06 Atlas Venture Fund IX, L.P. Beneficial Owner of More than 10% Class Sell 30000 16.77
2017-07-06 Formela (Jean-Francois) Director Sell 30000 16.77
2017-06-01 Dorsa (Caroline D) Director Buy 5000 12.42
2017-06-01 Bell (Graeme) Chief Financial Officer Buy 8400 12.37
2017-05-31 Bermingham (Nessan) Chief Executive Officer Buy 8400 11.95
2017-05-31 Leonard (John M) Officer and Director Buy 7800 12.06
2017-05-31 Rivera (José E) General Counsel Buy 8400 12.03
2017-05-31 Leonard (John M) Officer and Director Buy 600 12.09
2017-05-31 Karsen (Perry A) Director Buy 5000 11.99
2017-03-09 Formela (Jean-Francois) Director Sell 5504 14.06
2017-03-09 Atlas Venture Associates IX, L.P Beneficial Owner of More than 10% Class Sell 5504 14.06
2017-03-08 Atlas Venture Associates IX, L.P Beneficial Owner of More than 10% Class Sell 15628 13.85
2017-03-08 Formela (Jean-Francois) Director Sell 15628 13.85
2017-03-02 Novartis Institutes for BioMedic Beneficial Owner of More than 10% Class Buy 79245 --
2017-03-02 Atlas Venture Fund IX, L.P. Beneficial Owner of More than 10% Class Sell 700000 --
2016-05-10 Novartis Institutes for BioMedic Beneficial Owner of More than 10% Class Buy 492640 --
2016-05-10 Haurwitz (Rachel E. Ph.D.) Director and Beneficial Owner Buy 174806 --
2016-05-10 Novartis Institutes for BioMedic Beneficial Owner of More than 10% Class Buy 1724240 --
2016-05-10 Temasek Holdings Private Ltd Beneficial Owner of More than 10% Class Buy 300000 18.00
2016-05-10 Temasek Holdings Private Ltd Beneficial Owner of More than 10% Class Buy 490527 --
2016-05-10 Temasek Holdings Private Ltd Beneficial Owner of More than 10% Class Buy 300000 18.00
2016-05-10 Orbimed Advisors, L.L.C. Unknown Buy 564780 --
2016-05-10 Orbimed Advisors, L.L.C. Unknown Buy 191466 18.00
2016-05-10 Orbimed Advisors, L.L.C. Unknown Buy 1847400 --
2016-05-10 Orbimed Advisors, L.L.C. Unknown Buy 58534 18.00
2016-05-10 Orbimed Advisors, L.L.C. Unknown Buy 191466 18.00
第 页, 共 2 页 首页 上页 下页 末页

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Dimensional Fund Advisors LP 688227 1.42% 24918 3.76% 2019-07-31
Fidelity Management & Research Company 1872048 3.86% -352 -0.02% 2019-07-31
State Street Corporation 1777835 3.89% -536595 -23.18% 2019-03-31
Morgan Stanley - Brokerage Accounts 1964463 4.30% -267783 -12.00% 2019-03-31
Fidelity Management and Research Company 2222735 4.86% -155629 -6.54% 2019-03-31
FMR Inc 2259303 4.94% -155629 -6.44% 2019-03-31
Vanguard Group Inc 2812392 6.15% 66266 2.41% 2019-03-31
BlackRock Inc 3181719 6.96% 312981 10.91% 2019-03-31
ARK Investment Management LLC 7981198 17.46% 1179246 17.34% 2019-03-31
Ontario Teachers Pension Plan Board 1660000 3.63% -- -- 2019-03-31
BlackRock Fund Advisors 1727617 3.56% 40564 2.40% 2019-07-31
Atlas Venture Associates IX, LLC 1615321 3.53% -- -- 2019-03-31
Morgan Stanley Investment Management, Inc. 1496126 3.27% 23054 1.57% 2019-03-31
Nikko Asset Management Americas Inc 1071354 2.34% 1065374 17815.62% 2019-03-31
Sumitomo Mitsui Trust Holdings Inc 1046692 2.29% 1046692 -- 2019-03-31
SSGA Funds Management Inc 1092294 2.25% 20748 1.94% 2019-07-31
Chevy Chase Trust Holdings, Inc. 956511 2.09% 261175 37.56% 2019-03-31
Vanguard Investments Australia Ltd 1003874 2.07% 800 0.08% 2019-07-31
Temasek Holdings Ltd. 790527 1.73% -- -- 2019-03-31
Federated Investors Inc 667000 1.46% -- -- 2019-03-31
Federated Equity Mgmt Co. Of Penn 667000 1.46% -- -- 2019-07-31
BlackRock Asset Management Canada Ltd 705304 1.54% -508 -0.07% 2019-05-31
Geode Capital Management, LLC 718958 1.57% 377250 110.40% 2018-12-31
Deutsche Bank AG 635956 1.41% 273501 75.46% 2018-12-31
Fidelity Management Trust Co 602687 1.33% 5397 0.90% 2019-02-28
Orbimed Advisors, LLC 744600 1.65% -131400 -15.00% 2018-09-30
Regents Of The University Of California 524423 1.21% -- -- 2018-12-31
Farallon Capital Management, L.L.C. 550000 1.27% -290000 -34.52% 2018-09-30
Federated Global Inv Mgmt Corp 625300 1.44% 27200 4.55% 2018-06-30
BlackRock Institutional Trust Company NA 716149 1.65% 155951 27.84% 2018-06-30
Morgan Stanley & Co Inc 334731 0.78% 251459 301.97% 2018-06-30
Northern Trust Investments N A 366673 0.85% 182055 98.61% 2018-06-30
Baker Bros Advisors LP 546922 1.27% -286873 -34.41% 2018-06-30
Morgan Stanley Investment Management Inc 1716912 3.98% 58442 3.52% 2018-06-30
Atlas Venture Fund IX, LP 3579788 8.45% -850000 -19.19% 2017-12-31
State Street Corp 2696421 6.24% 1154809 74.91% 2018-06-30
Novartis AG 4277073 10.09% 147170 3.56% 2018-03-16
Caribou Biosciences, Inc. 4545000 10.72% -1048846 -18.75% 2017-12-31
Fidelity Institutional Asset Management 1151063 2.67% -51703 -4.30% 2018-03-31
Invesco PowerShares Capital Mgmt LLC 268551 0.62% 268551 -- 2018-03-31
Numeric Investors LLC 338448 0.80% 318014 1556.30% 2017-12-31
GMT Capital Corp 330533 0.78% -- -- 2017-12-31
Artal Group S A 175000 0.48% -75000 -30.00% 2017-09-30
Global Thematic Partners, LLC 502327 1.39% 502327 -- 2017-09-30
Granahan Investment Management Inc.. 130608 0.36% -155536 -54.36% 2017-12-31
SELECTRA MANAGEMENT COMPANY S.A. 90000 0.25% -- -- 2018-01-31
USAA Investment Management Company 92700 0.26% -- -- 2017-09-30
IP Management Company 91880 0.27% 91880 -- 2017-12-31
GSA Capital Partners LLP 73100 0.20% 16400 28.92% 2017-09-30
Morgan Stanley Smith Barney LLC 70460 0.20% 34082 93.69% 2017-09-30
Neuberger Berman LLC 60915 0.17% 11398 23.02% 2017-09-30
UBS Securities LLC 69624 0.19% 7320 11.75% 2017-09-30
Franklin Advisers Inc 300000 0.83% -- -- 2016-09-30
EcoR1 Capital, LLC 200858 0.56% -109837 -35.35% 2016-09-30
Goldman Sachs Asset Management LP 145994 0.41% 1992 1.38% 2016-09-30
Millennium Management LLC 134240 0.37% 134240 -- 2016-09-30
Sectoral Asset Management Inc 123159 0.34% -- -- 2016-09-30
Sabby Management LLC 104841 0.29% 104841 -- 2016-09-30
Tekla Capital Management LLC 71842 0.20% -15000 -17.27% 2016-09-30
BlackRock Advisors LLC 616456 1.71% 707 0.11% 2016-09-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Fidelity 156938 0.32% -6500 -3.98% 2019-06-30
ARK Innovation ETF 4827480 9.94% -26816 -0.55% 2019-06-30
ARK Genomic Revolution ETF 1840648 3.79% -42457 -2.25% 2019-06-30
SPDR 1059976 2.18% 20748 2.00% 2019-07-31
Vanguard Total Stock Market Index Fund 999703 2.06% 824 0.08% 2019-06-30
Vanguard Small Cap Index 909616 1.87% 109339 13.66% 2019-06-30
iShares Russell 2000 ETF 818206 1.69% 25560 3.22% 2019-07-30
Federated Kaufmann Fund 530000 1.09% -- -- 2019-03-31
Vanguard Small Cap Growth Index Fund 502235 1.03% 52117 11.58% 2019-06-30
Fidelity Growth Company Commingled Pool 498833 1.03% -20000 -3.85% 2019-06-30
Vanguard Extended Market Index Fund 455313 0.94% 1666 0.37% 2019-06-30
iShares Nasdaq Biotechnology ETF 451244 0.93% 7075 1.59% 2019-07-30
Morgan Stanley Inst Growth Port 449168 0.93% -- -- 2019-03-31
DFA US Small Cap Portfolio 305536 0.63% 20284 7.11% 2019-05-31
iShares Russell 2000 Growth ETF 238073 0.49% 9088 3.97% 2019-07-30
MS INVF US Growth Fund 182317 0.38% -- -- 2019-03-31
Selectra J. Lamarck Biotech 160000 0.33% 50000 45.45% 2019-07-31
FastForward Innovations Limited Ord 288458 0.63% 235313 442.78% 2018-09-30
iShares US Small Cap ETF (CAD-Hedged) 667325 1.46% -1116 -0.17% 2019-05-30
ARK Genomic Revolution Multi-Sector ETF 1861868 4.07% 162759 9.58% 2019-04-30
Vanguard Small Cap Index Fund 802487 1.76% 2244 0.28% 2019-04-30
State Street Russell Small/Mid Cap 148057 0.32% -- -- 2019-04-30
NT R2000 Growth Index Fund - Non-Lending 142615 0.32% -- -- 2019-03-31
State Street Russell Small Cap 135377 0.30% -- -- 2019-02-28
iShares Russell 2000 Value ETF 188452 0.42% -312 -0.17% 2018-06-21
Federated Kaufmann Small Cap Fund 122800 0.27% -- -- 2018-12-31
Candriam Eqs L Biotechnology 120000 0.28% -- -- 2018-12-31
Fidelity Global Innovators Cl 156701 0.36% 6152 4.09% 2018-03-31
Fidelity Special Situations Fund 335445 0.77% -55726 -14.25% 2018-03-31
Fidelity Special Situations Class 335445 0.77% -55726 -14.25% 2018-03-31
Invesco Dynamic Biotech & Genome ETF 301506 0.69% 38024 14.43% 2018-05-30
Vanguard Total Stock Mkt Idx 726184 1.68% -- -- 2018-07-31
iShares Nasdaq Biotechnology 488220 1.11% -930 -0.19% 2018-09-12
Federated Kaufmann R 500000 1.16% -- -- 2018-06-30
Morgan Stanley Inst Growth I 449168 1.04% -- -- 2018-06-30
Vanguard Small Cap Growth Index Inv 401316 0.93% 5573 1.41% 2018-07-31
iShares Russell 2000 Growth 329092 0.75% -317 -0.10% 2018-09-12
Tekla Healthcare Investors 115851 0.27% -- -- 2018-06-30
Vanguard Extended Market Idx Inv 276267 0.64% 5900 2.18% 2018-07-31
Federated Kaufmann Small Cap A 112200 0.26% 27200 32.00% 2018-06-30
Transamerica Capital Growth A 112584 0.26% 9945 9.69% 2018-07-31
Met Invt Ser MorganStanley Md Cp Gr A 105218 0.24% -9000 -7.88% 2018-06-30
iShares Micro-Cap 89050 0.20% -- -- 2018-09-05
Fidelity Spartan 91763 0.21% -- -- 2018-06-30
iShares Russell 2000 Value 188452 0.48% -312 -0.17% 2018-06-21
Franklin Biotechnology Discovery A 80195 0.22% -- -- 2018-04-30
PowerShares Dynamic Biotech & Genome ETF 263482 0.79% -- -- 2018-05-24
JNL Multi-Manager Small Cap Growth B 63800 0.15% -78400 -55.13% 2017-12-31
Fidelity Advisor 139192 0.33% -- -- 2018-02-28
Schwab US Small-Cap ETF 54532 0.19% 81 0.15% 2018-03-08
Morgan Stanley Inst Small Co Gr I 83369 0.23% 9526 12.90% 2017-09-30
Vanguard Health Care ETF 46838 0.13% -506 -1.07% 2017-12-31
DFA US Small Cap I 28982 0.08% -- -- 2017-10-31
Goldman Sachs Small/Mid Cap Growth A 124776 0.35% -12920 -9.38% 2016-12-31
AXA/Morgan Stanley Small Cap Growth K 26045 0.07% -- -- 2016-11-30
BlackRock Health Sciences 30613 0.08% -- -- 2016-09-30

Perry A. Karsen Perry A. Karsen is a businessperson who has been at the head of 8 different companies. He is Chairman of Jounce Therapeutics, Inc., Chairman of Intellia Therapeutics, Inc. and President & Director at Stalar 3, Inc. He is also on the board of 5 other companies. In the past he held the position of Chairman at Pliant Therapeutics, Inc., Chief Operating Officer & Executive Vice President for Celgene Corp. Chief Executive Officer at Anthrogenesis Corp. Chief Executive Officer for Celgene Cellular Therapeutics and Chief Operations Officer & EVP at Celgene LLC (which are all subsidiaries of Celgene Corp.), General Partner of FirstMark Capital LLC, Commercial Director-Europe Region at Abbott Laboratories, Member of Roche Holding AG and Director-Business Development of Genentech, Inc. (a subsidiary of Roche Holding AG), Senior VP & Head-Worldwide Business Development at Celgene Corp. Chief Executive Officer at Anthrogenesis Corp. Chief Executive Officer at Celgene Cellular Therapeutics and Chief Operations Officer & EVP at Celgene LLC (which are all subsidiaries of Celgene Corp.), VP-Strategic Business Analysis & Development at Bristol-Myers Squibb Co., Venture Partner at Third Rock Ventures LLC, Executive Chairman of OncoMed Pharmaceuticals, Inc., President & Chief Executive Officer for Pearl Therapeutics, Inc., Senior Vice President-Business Development of Human Genome Sciences, Inc. and Senior Vice President-Sales & Marketing at Zimmer, Inc. Mr. Karsen received a graduate degree from Duke University, an undergraduate degree from the University of Illinois and an MBA from Kellogg School of Management.
Caroline D. Dorsa Caroline D. Dorsa is on the board of Biogen, Inc. and 10 other companies. In the past she was Chief Financial Officer & Senior Vice President at Gilead Sciences, Inc., Chief Financial Officer & Executive Vice President at Public Service Enterprise Group, Inc. Chief Financial Officer, Director & Executive VP at PSEG Power LLC, Chief Financial Officer & Executive Vice President for Public Service Electric & Gas Co. Chief Financial Officer of PSEG Energy Holdings LLC and Chief Financial Officer & Executive Vice President for PSEG Services Corp. (which are all subsidiaries of Public Service Enterprise Group, Inc.), SVP-Global Human, Health, Strategy & Integration at Merck & Co., Inc. and Chief Financial Officer & Senior Vice President of Avaya, Inc. She received an undergraduate degree from Colgate University and an MBA from Columbia Business School.
Jean-Francois B. Formela Founder of Translate Bio, Inc., Egalet Corp. and Adnexus, Jean-Francois B. Formela presently holds the position of Partner at Atlas Venture, Inc. and Chairman of IFM Therapeutics LLC. He is also on the board of 19 other companies. In his past career Dr. Formela held the position of Chairman of Egalet Corp. and Chairman at Egalet Ltd. (a subsidiary of Egalet Corp.), Senior Director-Medical Marketing at Schering-Plough Corp. and Director at Adnexus. Dr. Formela received a doctorate from Universit�0�1�0�8 Paris-Sud 11 and an MBA from Columbia University.
Fred E. Cohen Dr. Fred E. Cohen is an Advisor at CHV Capital, Inc., Managing Director & Partner at Tarrant Capital IP LLC, Partner at TPG Capital Management LP, Chairman at Cell Design Labs, Inc., a Managing Director at The Plastics Group, Inc., a Member at American Academy of Arts & Sciences, a Member at American Society for Clinical Investigation, a Member at Association of American Physicians, a Member at Institute of Medicine and a Member at National Academy of Medicine. He is on the Board of Directors at BioCryst Pharmaceuticals, Inc., Tandem Diabetes Care, Inc., Roka Bioscience, Inc., Aptalis Holdings, Inc., Veracyte, Inc., CareDx, Inc., Five Prime Therapeutics, Inc., Genomic Health, Inc., Acumen, Inc., Aptalis Pharma, Inc., K�0�1�0�8mia, Inc., Matrix Pharmaceuticals, Inc., Progyny, Inc., Quintiles Transnational Corp., Rapid Micro Biosystems, Inc. and Autistica. Dr. Cohen was previously employed as an Independent Director by Quintiles Transnational Holdings, Inc., an Independent Director by CardioDx, Inc., a Professor by The University of California, San Francisco, Professor-Medicine & Pharmacology by University of California, Berkeley, and Senior Director-Business Development by Kosan Biosciences, Inc. He also served on the board at Anaborex, Inc., Aptalis Pharma Canada, Inc., Mylan Laboratories Ltd., Nodality, Inc. and ProteoGenix, Inc. He received his undergraduate degree from Yale University, a doctorate degree from Stanford University and a doctorate degree from the University of Oxford.
John M. Leonard Currently, John M. Leonard is President, Chief Executive Officer & Director at Intellia Therapeutics, Inc. Dr. Leonard is also on the board of Biotechnology Innovation Organization, IFM Therapeutics LLC and IQVIA Holdings, Inc. In his past career he was SVP-Pharmaceuticals, Research & Development at Abbott Laboratories, SVP-Global Pharmaceutical Research & Development at AbbVie, Inc. and Senior Director-Clinical Research at G.H. Besselaar Associates. Dr. Leonard received an undergraduate degree from the University of Wisconsin and a doctorate from The Johns Hopkins University School of Medicine.
Frank A. G. M. Verwiel Frank A. G. M. Verwiel is a Netherlands; Dutch businessperson who has been at the helm of 5 different companies. Currently, Dr. Verwiel is Chairman of ObsEva SA and President of Aptalis Pharma US, Inc. He is also on the board of Achillion Pharmaceuticals, Inc., Bavarian Nordic A, Bavarian Nordic GmbH and Intellia Therapeutics, Inc. Frank A. G. M. Verwiel previously occupied the position of VP-Hypertension & Worldwide Human Health Marketing at Merck & Co., Inc., President & Chief Executive Officer for Aptalis Pharma SAS, President, Chief Executive Officer & Director at Aptalis Pharma, Inc., President, Chief Executive Officer & Director at Aptalis Holdings, Inc. and Director & Director-Health Section Governing Board at Biotechnology Innovation Organization. Frank A. G. M. Verwiel received an MBA from INSEAD and a doctorate from Erasmus University Rotterdam.
John M. Leonard Currently, John M. Leonard is President, Chief Executive Officer & Director at Intellia Therapeutics, Inc. Dr. Leonard is also on the board of Biotechnology Innovation Organization, IFM Therapeutics LLC and IQVIA Holdings, Inc. In his past career he was SVP-Pharmaceuticals, Research & Development at Abbott Laboratories, SVP-Global Pharmaceutical Research & Development at AbbVie, Inc. and Senior Director-Clinical Research at G.H. Besselaar Associates. Dr. Leonard received an undergraduate degree from the University of Wisconsin and a doctorate from The Johns Hopkins University School of Medicine.
Graeme Bell Mr. Graeme Bell is a CFO, Principal Accounting Officer & Executive VP at Intellia Therapeutics, Inc. and a Chief Financial Officer & Executive Vice President at Anacor Pharmaceuticals, Inc. Mr. Bell was previously employed as a Director-Investor Relations by Merck & Co., Inc. and a Director-Claims Development by Direct Group Ltd. He received his MBA from the University of Durham.
Caroline D. Dorsa Caroline D. Dorsa is on the board of Biogen, Inc. and 10 other companies. In the past she was Chief Financial Officer & Senior Vice President at Gilead Sciences, Inc., Chief Financial Officer & Executive Vice President at Public Service Enterprise Group, Inc. Chief Financial Officer, Director & Executive VP at PSEG Power LLC, Chief Financial Officer & Executive Vice President for Public Service Electric & Gas Co. Chief Financial Officer of PSEG Energy Holdings LLC and Chief Financial Officer & Executive Vice President for PSEG Services Corp. (which are all subsidiaries of Public Service Enterprise Group, Inc.), SVP-Global Human, Health, Strategy & Integration at Merck & Co., Inc. and Chief Financial Officer & Senior Vice President of Avaya, Inc. She received an undergraduate degree from Colgate University and an MBA from Columbia Business School.
Glenn Goddard Presently, Glenn Goddard occupies the position of Executive VP, Chief Financial & Accounting Officer at Intellia Therapeutics, Inc. In his past career Mr. Goddard occupied the position of Senior Vice President-Finance at Agios Pharmaceuticals, Inc., Chief Financial Officer at Generation Bio Co., Controller for ImmunoGen, Inc., Vice President-Finance at Archemix Corp., Principal at Ernst & Young LLP and Principal at Feeley & Driscoll PC. Glenn Goddard received an undergraduate degree from Bentley University.
Glenn Goddard Presently, Glenn Goddard occupies the position of Executive VP, Chief Financial & Accounting Officer at Intellia Therapeutics, Inc. In his past career Mr. Goddard occupied the position of Senior Vice President-Finance at Agios Pharmaceuticals, Inc., Chief Financial Officer at Generation Bio Co., Controller for ImmunoGen, Inc., Vice President-Finance at Archemix Corp., Principal at Ernst & Young LLP and Principal at Feeley & Driscoll PC. Glenn Goddard received an undergraduate degree from Bentley University.
Jose E. Rivera Currently, Jose E. Rivera occupies the position of Executive Vice President & General Counsel at Intellia Therapeutics, Inc. In the past he occupied the position of Head-IP Group at Abbott Laboratories and Vice President, Chief Ethics & Compliance Officer at AbbVie, Inc. He received a graduate degree from Harvard Law School and an undergraduate degree from Boston College.
John M. Leonard Currently, John M. Leonard is President, Chief Executive Officer & Director at Intellia Therapeutics, Inc. Dr. Leonard is also on the board of Biotechnology Innovation Organization, IFM Therapeutics LLC and IQVIA Holdings, Inc. In his past career he was SVP-Pharmaceuticals, Research & Development at Abbott Laboratories, SVP-Global Pharmaceutical Research & Development at AbbVie, Inc. and Senior Director-Clinical Research at G.H. Besselaar Associates. Dr. Leonard received an undergraduate degree from the University of Wisconsin and a doctorate from The Johns Hopkins University School of Medicine.
Jesse Goodman Jesse Goodman is on the board of GlaxoSmithKline Plc, Center for Biologics Evaluation & Research and Intellia Therapeutics, Inc. and President & Director at The United States Pharmacopeia, Member-Regulatory Working Group at National Academy of Medicine of United States, Member-Regulatory Working Group at Coalition for Epidemic Preparedness Innovations and Professor at Georgetown University. In the past Jesse Goodman occupied the position of Chief Scientist at US Food & Drug Administration and Professor at the University of Minnesota. He received an undergraduate degree from Harvard College, a doctorate from Albert Einstein College of Medicine, Inc. and a graduate degree from the University of Minnesota.
Perry A. Karsen Perry A. Karsen is a businessperson who has been at the head of 8 different companies. He is Chairman of Jounce Therapeutics, Inc., Chairman of Intellia Therapeutics, Inc. and President & Director at Stalar 3, Inc. He is also on the board of 5 other companies. In the past he held the position of Chairman at Pliant Therapeutics, Inc., Chief Operating Officer & Executive Vice President for Celgene Corp. Chief Executive Officer at Anthrogenesis Corp. Chief Executive Officer for Celgene Cellular Therapeutics and Chief Operations Officer & EVP at Celgene LLC (which are all subsidiaries of Celgene Corp.), General Partner of FirstMark Capital LLC, Commercial Director-Europe Region at Abbott Laboratories, Member of Roche Holding AG and Director-Business Development of Genentech, Inc. (a subsidiary of Roche Holding AG), Senior VP & Head-Worldwide Business Development at Celgene Corp. Chief Executive Officer at Anthrogenesis Corp. Chief Executive Officer at Celgene Cellular Therapeutics and Chief Operations Officer & EVP at Celgene LLC (which are all subsidiaries of Celgene Corp.), VP-Strategic Business Analysis & Development at Bristol-Myers Squibb Co., Venture Partner at Third Rock Ventures LLC, Executive Chairman of OncoMed Pharmaceuticals, Inc., President & Chief Executive Officer for Pearl Therapeutics, Inc., Senior Vice President-Business Development of Human Genome Sciences, Inc. and Senior Vice President-Sales & Marketing at Zimmer, Inc. Mr. Karsen received a graduate degree from Duke University, an undergraduate degree from the University of Illinois and an MBA from Kellogg School of Management.
Perry A. Karsen Perry A. Karsen is a businessperson who has been at the head of 8 different companies. He is Chairman of Jounce Therapeutics, Inc., Chairman of Intellia Therapeutics, Inc. and President & Director at Stalar 3, Inc. He is also on the board of 5 other companies. In the past he held the position of Chairman at Pliant Therapeutics, Inc., Chief Operating Officer & Executive Vice President for Celgene Corp. Chief Executive Officer at Anthrogenesis Corp. Chief Executive Officer for Celgene Cellular Therapeutics and Chief Operations Officer & EVP at Celgene LLC (which are all subsidiaries of Celgene Corp.), General Partner of FirstMark Capital LLC, Commercial Director-Europe Region at Abbott Laboratories, Member of Roche Holding AG and Director-Business Development of Genentech, Inc. (a subsidiary of Roche Holding AG), Senior VP & Head-Worldwide Business Development at Celgene Corp. Chief Executive Officer at Anthrogenesis Corp. Chief Executive Officer at Celgene Cellular Therapeutics and Chief Operations Officer & EVP at Celgene LLC (which are all subsidiaries of Celgene Corp.), VP-Strategic Business Analysis & Development at Bristol-Myers Squibb Co., Venture Partner at Third Rock Ventures LLC, Executive Chairman of OncoMed Pharmaceuticals, Inc., President & Chief Executive Officer for Pearl Therapeutics, Inc., Senior Vice President-Business Development of Human Genome Sciences, Inc. and Senior Vice President-Sales & Marketing at Zimmer, Inc. Mr. Karsen received a graduate degree from Duke University, an undergraduate degree from the University of Illinois and an MBA from Kellogg School of Management.
Frank A. G. M. Verwiel Frank A. G. M. Verwiel is a Netherlands; Dutch businessperson who has been at the helm of 5 different companies. Currently, Dr. Verwiel is Chairman of ObsEva SA and President of Aptalis Pharma US, Inc. He is also on the board of Achillion Pharmaceuticals, Inc., Bavarian Nordic A, Bavarian Nordic GmbH and Intellia Therapeutics, Inc. Frank A. G. M. Verwiel previously occupied the position of VP-Hypertension & Worldwide Human Health Marketing at Merck & Co., Inc., President & Chief Executive Officer for Aptalis Pharma SAS, President, Chief Executive Officer & Director at Aptalis Pharma, Inc., President, Chief Executive Officer & Director at Aptalis Holdings, Inc. and Director & Director-Health Section Governing Board at Biotechnology Innovation Organization. Frank A. G. M. Verwiel received an MBA from INSEAD and a doctorate from Erasmus University Rotterdam.
Andrew Schiermeier Mr. Andrew Schiermeier is a Chief Operating Officer at Intellia Therapeutics, Inc. Mr. Schiermeier was previously employed as a Senior CP & Head-Oncology Business by Merck KGaA and a Chief Operating Officer by Aura Biosciences, Inc. He received his graduate degree from Stanford University, an MBA from the College des Ingenieurs and a doctorate degree from Harvard University.
Li Lina Presently, Li Lina is Senior Manager-Investor Relations at Intellia Therapeutics, Inc.
Laura Sepp-Lorenzino Laura Sepp-Lorenzino holds the position of Chief Scientific Officer & Executive VP at Intellia Therapeutics, Inc. She received a graduate degree and a doctorate from New York University and an undergraduate degree from Universidad de Buenos Aires.
Walid Awni Dr. Walid Awni is a SVP, Head-Preclinical & Clinical Sciences at Intellia Therapeutics, Inc. He received his doctorate degree from the University of Minnesota.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐